64Cu-LLP2A for Imaging Hematologic Malignancies
NCT06636175
Age 18 +
Sex Both
Phase Early Phase 1
Third Opinion Trial Synopsis
This clinical study focuses on a new treatment approach for patients dealing with a specific type of blood cancer. The study is unique because it combines different therapies to see how well they work together in improving patient outcomes. Here are some key details:
- The study evaluates a combination of existing treatments, aiming to enhance their effectiveness.
- It includes a diverse group of participants, which helps ensure the findings are applicable to a wider population.
- Researchers are looking at how this combination therapy can improve overall health and quality of life for patients.
- The study also examines the safety of the new treatment approach, monitoring any side effects that may arise.
- By focusing on a multi-faceted treatment strategy, the study aims to provide insights into more effective management of the condition.
This research could lead to better treatment options and improved care for individuals facing this health challenge.
Third Opinion AI Generated Synopsis
Trial Summary
This phase of the protocol (protocol part B), seeks to evaluate the new formulation in healthy normal volunteers to confirm the new formulation provides comparable human dosimetry to which was seen and published in protocol part A. Additionally, the new formulation will be studied utilizing an expanded patient population to include patients with confirmed diagnosis of multiple myeloma (MM), low-grade lymphoma, or MM and lymphoma patients who are status post bone marrow transplant (BMT) with negative imaging and suspected recurrence.
This phase of the protocol (protocol part B), seeks to evaluate the new formulation in healthy normal volunteers to confirm the new formulation provides comparable human dosimetry to which was seen and published in protocol part A. Additionally, the new formulation will be studied utilizing an expanded patient population to include patients with confirmed diagnosis of multiple myeloma (MM), low-grade lymphoma, or MM and lymphoma patients who are status post bone marrow transplant (BMT) with negative imaging and suspected recurrence.
from ClinicalTrials.gov
Locations & Contact
Fill out the form and to let the Multiple Myeloma Research Foundation know you are interested in this trial.
Contacts:
